Key Points
- Director sale: Guardant Health director Medina Manuel Hidalgo sold 1,300 shares on March 6 at an average price of $91.54 for $119,002, cutting his holding to 1,193 shares (a 52.15% decrease) and disclosing the trade in an SEC filing.
- Quarterly results: Guardant reported Q4 EPS of ($0.50), missing estimates by $0.07, while revenue of $281.27 million beat expectations and rose 39.4% year‑over‑year.
- Analyst sentiment: Multiple firms have raised price targets (Citigroup to $150, Leerink to $180, etc.), the consensus is a "Moderate Buy" with an average target of $122.57, and the stock has a market cap of about $11.96 billion and a 1‑year range of $34.88–$120.74.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Medina Manuel Hidalgo sold 1,300 shares of the stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $91.54, for a total transaction of $119,002.00. Following the sale, the director owned 1,193 shares in the company, valued at $109,207.22. This represents a 52.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Guardant Health Price Performance
Shares of NASDAQ:GH opened at $91.20 on Tuesday. Guardant Health, Inc. has a 1 year low of $34.88 and a 1 year high of $120.74. The stock has a market capitalization of $11.96 billion, a price-to-earnings ratio of -27.55 and a beta of 1.67. The company's 50 day simple moving average is $105.09 and its 200 day simple moving average is $89.33.
Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to analysts' expectations of $269.74 million. Guardant Health's revenue was up 39.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.62) EPS. As a group, analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.
Institutional Investors Weigh In On Guardant Health
Hedge funds and other institutional investors have recently bought and sold shares of the company. Allworth Financial LP increased its holdings in Guardant Health by 19.5% in the 3rd quarter. Allworth Financial LP now owns 844 shares of the company's stock worth $53,000 after purchasing an additional 138 shares in the last quarter. Eastern Bank boosted its stake in shares of Guardant Health by 6.9% during the fourth quarter. Eastern Bank now owns 2,160 shares of the company's stock valued at $221,000 after purchasing an additional 139 shares in the last quarter. TD Waterhouse Canada Inc. boosted its stake in shares of Guardant Health by 3.2% during the third quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company's stock valued at $306,000 after purchasing an additional 151 shares in the last quarter. Xponance LLC grew its holdings in shares of Guardant Health by 2.1% during the fourth quarter. Xponance LLC now owns 9,630 shares of the company's stock worth $984,000 after purchasing an additional 199 shares during the last quarter. Finally, Danske Bank A S grew its holdings in shares of Guardant Health by 20.0% during the fourth quarter. Danske Bank A S now owns 1,200 shares of the company's stock worth $123,000 after purchasing an additional 200 shares during the last quarter. Institutional investors own 92.60% of the company's stock.
Analysts Set New Price Targets
GH has been the subject of several recent analyst reports. Citigroup upped their price objective on Guardant Health from $135.00 to $150.00 and gave the stock a "buy" rating in a research report on Friday, February 20th. Guggenheim boosted their target price on Guardant Health from $115.00 to $135.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. JPMorgan Chase & Co. increased their target price on shares of Guardant Health from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Friday, February 20th. Leerink Partners raised their price target on shares of Guardant Health from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Friday, February 20th. Finally, BTIG Research lifted their price target on shares of Guardant Health from $140.00 to $145.00 and gave the company a "buy" rating in a report on Friday, February 20th. Twenty-one research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $122.57.
View Our Latest Stock Analysis on GH
About Guardant Health
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
